CAR T cell therapy China entails the modification of a patient’s T cells, empowering them with a Chimeric Antigen Receptor (CAR) to specifically target cancer cells. China's substantial investments in biomedical research have fostered a fertile ground for advancing CAR T cell technology. The nation boasts numerous research institutions and biotech firms dedicated to pushing the boundaries of CAR T cell therapy, propelling China to the forefront of global research in this field.
read more..